Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer
NCT01911988 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2016-10-20
Summary
The purpose of this study is to determine association between Peripheral Immune Cells(PIC) and recurrence in stage II/III colorectal cancer
Conditions
Sponsors & Collaborators
-
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
lead OTHER
Principal Investigators
-
Long Cui, MD, PhD · Medical Center of Colon&Rectal Cancers, Shanghai Xinhua Hospital affiliated to Shanghai Jiaotong University
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-06-30
- Primary Completion
- 2020-12-31
Countries
- China
Study Locations
More Related Trials
-
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751914 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
NCT05450029 ·Status: RECRUITING ·Phase: PHASE2
-
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
NCT06751953 ·Status: RECRUITING ·Phase: NA
-
CRC Post-surgical Assessment and Recurrence Monitoring
NCT03334890 ·Status: UNKNOWN
-
Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer
NCT01929499 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer
NCT03904537 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149 ·Status: UNKNOWN
-
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
NCT05414461 ·Status: COMPLETED ·Phase: PHASE2
-
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
NCT03638297 ·Status: RECRUITING ·Phase: PHASE2
-
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
NCT06557668 ·Status: RECRUITING
-
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
NCT06215677 ·Status: RECRUITING ·Phase: NA
-
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
NCT06751940 ·Status: RECRUITING ·Phase: NA
-
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
NCT05287165 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
NCT02415699 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
NCT05371197 ·Status: UNKNOWN ·Phase: PHASE2
-
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
NCT04301557 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
NCT06980350 ·Status: COMPLETED
-
Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
NCT02817178 ·Status: COMPLETED ·Phase: NA
-
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
NCT04833387 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
NCT03493880 ·Status: UNKNOWN
-
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
NCT05914389 ·Status: RECRUITING ·Phase: PHASE2
-
The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer
NCT05015296 ·Status: UNKNOWN
-
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
NCT06098560 ·Status: RECRUITING
-
Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
NCT05815290 ·Status: RECRUITING ·Phase: PHASE2